Bli medlem
Bli medlem

Du är här


Hansa Medical: Hansa Medical publishes the Annual Report for 2015

Hansa Medical's Annual Report for 2015 is now available on the
company's website,

The Annual Report is posted to shareholders and other stakeholders who
specifically request it. For further information please contact the
company by telephone +46 46-16 56 70 or e-mail

The information in this press release is disclosed pursuant to the
Swedish Securities Markets Act and/or the Swedish Financial
Instruments Trading Act. The information was released for public
disclosure on March 31, 2016 at 12.00 CET.

For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: 46 70-633 30 42

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focusing on novel
immunomodulatory enzymes. The lead project IdeS is an
antibody-degrading enzyme in clinical development, with potential use
in transplantation and rare autoimmune diseases. Additional projects
focus on development of new antibody modulating enzymes, as well as
HBP, a diagnostic biomarker for prediction of severe sepsis at
emergency departments that is already introduced on the market. The
company is based in Lund, Sweden. Hansa Medical's share (ticker:
HMED) is listed on Nasdaq Stockholm.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.